Compare Teladoc Health Inc (TDOC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teladoc Health Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Teladoc Health Inc trades at $5.69 (market cap $1.01B), while State Street SPDR S&P Biotech ETF trades at $154.31 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 10× Teladoc Health Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Teladoc Health Inc for 39 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| TDOC | XBI | |
|---|---|---|
Market Cap | $1.01B | $10.11B |
Volume | 4,668,477 | 12,903,266 |
Sector | Health | Broad Market / Factor |
52-Week High | $9.72 | $169.55 |
52-Week Low | $4.47 | $104.99 |
Typical Hold Time | 39 Days | 37 Days |
Enterprise Value | $1.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teladoc Health (TDOC) trades at $5.67, showing modest daily gains but remains near multi-year lows with a bearish technical outlook. The company maintains strong revenue around $2.5B annually but continues to report net losses, with a -7.13% net margin in 2026. Recent management changes include the appointment of a new CFO, while analyst sentiment remains cautious despite a consensus price target of $8.83 representing 56% upside potential.
TDOC presents a high-risk opportunity with significant upside potential if the company can achieve profitability turnaround. The stock trades at discounted valuations (P/S 0.4x, P/B 0.77x) but faces execution risks from ongoing losses, BetterHelp segment challenges, and potential legal investigations. Free cash flow generation and integrated care growth provide stabilization, though sustained profitability remains the key catalyst needed for sustained recovery.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
